The use of artificial intelligence (AI) in the biopharma industry has the potential to revolutionise drug discovery and development, as well as improve patient care.
Tech company CytoReason has announced it has signed a multi-year, multimillion dollar deal with Sanofi to deliver artificial intelligence (AI) for drug discovery and development in the fiel
